At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 4 enrolled
Drug / intervention
Ixekizumabbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum
In Brief
A Phase 2 clinical trial evaluating Ixekizumab for Pyoderma Gangrenosum. Completed, enrolled 4 participants across 1 site.
Detailed Summary
An Open-Label, Proof-Of-Concept, Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPyoderma Gangrenosum
CountriesUnited States
CollaboratorsEli Lilly and Company
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedMay 2017
Enrollment StartMay 2017
Primary CompletionAug 2018
TodayJul 2026
First PostedMay 2, 2017
Enrollment StartMay 4, 2017
Primary CompletionAug 16, 2018
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 9.2 years ago
Interventions
Ixekizumabbiological
Injection